Siltuximab (CNTO 328): a promising option for human malignancies
نویسندگان
چکیده
منابع مشابه
Siltuximab (CNTO 328): a promising option for human malignancies
Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of siltuximab in the treatment of human malignancies. We also provide our recommendations for siltuximab...
متن کاملProduction of Holmium-166 DOTMP: A promising agent for bone marrow ablation in hematologic malignancies
Intoduction: Therapeutic radiopharmaceuticals are radiolabeled molecules to deliver sufficient doses of ionizing radiation to specific disease sites such as bone metastases, brain and liver tumors and bone marrows malignancies including multiple myeloma. Among some therapeutic radiopharmaceuticals, 166Ho-1,4,7,10 -tetraazacyclo dodecane-1,4,7,10 tetraethy...
متن کاملInhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
PURPOSE Inhibition of the proteasome leads to the activation of survival pathways in addition to those that promote cell death. We hypothesized that down-regulation of interleukin-6 (IL-6) signaling using the monoclonal antibody CNTO 328 would enhance the antitumor activity of the proteasome inhibitor bortezomib in multiple myeloma by attenuating inducible chemoresistance. EXPERIMENTAL DESIGN...
متن کاملPhototherapy: a promising treatment option for skin sclerosis in scleroderma?
In systemic sclerosis (SSc; scleroderma) fibrosis of the skin can lead to considerable morbidity. No significant improvement has been reported from studies investigating antifibrotic therapies so far. In dermatology, phototherapy with ultraviolet (UV) irradiation is successfully used for treatment of several diseases because of its anti-inflammatory as well as immunosuppressive mechanisms, and ...
متن کاملNeurostimulation. A promising therapeutic option for medically refractory epilepsy.
Epilepsy is a common and serious chronic neurological disorder, affecting around 65 million people worldwide. Despite the advances in pharmacologic treatments for epilepsy, approximately 30% of the patients remain medically refractory and continue to have seizures on medications, in such cases, other treatment approaches are necessary. Resection surgery can be an alternative in many patients to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Design, Development and Therapy
سال: 2015
ISSN: 1177-8881
DOI: 10.2147/dddt.s86438